# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce HBV
- describe HBV infection
- discuss current treatments
- highlight limitations of current treatments
- discuss therapeutic vaccination
- highlight need for new treatment
- summarize unmet medical need

## BRIEF SUMMARY OF THE INVENTION

- introduce immunogenic compositions
- describe non-naturally occurring nucleic acid molecule
- provide first embodiment of nucleic acid molecule
- provide second embodiment of nucleic acid molecule
- provide third embodiment of nucleic acid molecule
- provide fourth embodiment of nucleic acid molecule
- provide fifth embodiment of nucleic acid molecule
- provide sixth embodiment of nucleic acid molecule
- provide seventh embodiment of nucleic acid molecule
- provide eighth embodiment of nucleic acid molecule
- provide ninth embodiment of nucleic acid molecule
- provide tenth embodiment of nucleic acid molecule
- provide eleventh embodiment of nucleic acid molecule
- provide twelfth embodiment of nucleic acid molecule
- provide thirteenth embodiment of nucleic acid molecule
- provide fourteenth embodiment of nucleic acid molecule
- provide fifteenth embodiment of nucleic acid molecule
- provide sixteenth embodiment of nucleic acid molecule
- provide seventeenth embodiment of nucleic acid molecule
- provide eighteenth embodiment of nucleic acid molecule
- provide nineteenth embodiment of nucleic acid molecule
- provide twentieth embodiment of nucleic acid molecule
- provide twenty-first embodiment of nucleic acid molecule
- provide twenty-second embodiment of nucleic acid molecule
- provide twenty-third embodiment of nucleic acid molecule
- provide twenty-fourth embodiment of nucleic acid molecule
- provide twenty-fifth embodiment of nucleic acid molecule
- provide twenty-sixth embodiment of nucleic acid molecule
- provide twenty-seventh embodiment of nucleic acid molecule
- provide twenty-eighth embodiment of nucleic acid molecule
- provide twenty-ninth embodiment of nucleic acid molecule
- provide thirtieth embodiment of nucleic acid molecule
- provide thirty-first embodiment of nucleic acid molecule
- provide thirty-second embodiment of nucleic acid molecule
- provide thirty-third embodiment of nucleic acid molecule
- provide thirty-fourth embodiment of nucleic acid molecule
- provide thirty-fifth embodiment of nucleic acid molecule
- provide thirty-sixth embodiment of nucleic acid molecule

## DETAILED DESCRIPTION OF THE INVENTION

- cite publications and patents
- discuss documents and materials
- define technical and scientific terms
- clarify singular and plural references
- explain "at least" phrase
- discuss equivalents to specific embodiments
- define "comprise" and variations
- explain "consisting of" and "consisting essentially of"
- define "and/or" conjunctive term
- discuss numerical values and ranges
- explain "% sequence identity" phrase
- discuss aligning protein sequences
- define "in combination" and related phrases
- explain simultaneous administration
- discuss separate compositions and sequential administration
- define "non-naturally occurring" nucleic acid or polypeptide
- explain synthesized or manipulated nucleic acid or polypeptide
- define "subject" and preferred mammals
- explain "operably linked" components
- discuss various embodiments and combinations
- introduce hepatitis B virus (HBV)
- describe HBV proteins and functions
- explain HBV genome and replication
- discuss HBV serotypes and genotypes
- describe HBV distribution by geographic region
- discuss HBV genotypes in Asia
- discuss HBV genotypes in Africa and India
- discuss HBV genotypes in Europe and Africa

### HBV Antigens

- define HBV antigen
- describe HBV antigen capabilities
- introduce HBV core antigen
- describe HBV core antigen structure
- define truncated HBV core antigen
- describe truncated HBV core antigen modifications
- introduce consensus sequence
- describe consensus sequence derivation
- define consensus antigen
- describe exemplary truncated HBV core antigen
- introduce HBV polymerase antigen
- describe HBV polymerase antigen structure
- define HBV Pol antigen modifications
- describe inactivated HBV Pol antigen
- introduce mutations in polymerase domain
- introduce mutations in RNaseH domain
- describe preferred HBV Pol antigen
- introduce consensus HBV Pol antigen
- describe exemplary HBV Pol consensus antigen
- introduce fusion protein
- describe fusion of HBV core antigen and HBV polymerase antigen
- describe linker in fusion protein
- conclude HBV antigen description
- define linker
- describe linker composition
- specify exemplary linkers
- describe fusion protein capabilities
- specify fusion protein composition
- describe preferred fusion protein embodiment
- specify signal sequence
- define HBV surface antigens
- describe HBV surface protein gene structure
- specify HBV surface antigen capabilities
- describe preferred HBV surface antigen embodiment
- specify S-surface antigen composition
- describe S-surface antigen capabilities
- specify M-surface antigen composition
- describe M-surface antigen capabilities
- specify L-surface antigen composition
- describe L-surface antigen capabilities
- specify HBV surface antigen fragments
- describe HBV surface antigen combinations
- specify exemplary HBV surface antigen sequence

### Polynucleotides and Vectors

- introduce non-naturally occurring nucleic acid molecule
- define polynucleotide sequence
- describe vector composition
- specify polynucleotide forms
- describe polynucleotide uses
- introduce truncated HBV core antigen
- specify amino acid sequence identity
- provide exemplary polynucleotide sequences
- introduce HBV polymerase antigen
- specify amino acid sequence identity
- provide exemplary polynucleotide sequences
- introduce fusion protein
- specify fusion protein composition
- provide exemplary polynucleotide sequences
- introduce S-surface antigen
- specify amino acid sequence identity
- provide exemplary polynucleotide sequences
- introduce HBV surface antigen
- define polynucleotides and vectors
- describe HBV surface antigen encoding polynucleotides
- introduce vectors for HBV antigen expression
- define expression vectors
- describe regulatory sequences in vectors
- introduce non-viral vectors
- describe DNA plasmids as non-viral vectors
- list examples of DNA plasmids
- describe modification of DNA plasmids
- introduce viral vectors
- describe adenoviral vectors
- list examples of adenoviral vectors
- describe preparation of recombinant viral vectors
- introduce codon-optimization of polynucleotides
- describe regulatory elements in vectors
- introduce expression cassettes
- describe components of expression cassettes
- define operably linked polynucleotides
- introduce promoters in expression cassettes
- describe types of promoters
- describe sources of promoters
- describe location of promoters in expression cassettes
- conclude vector design
- list promoters
- describe CMV promoter
- list human gene promoters
- describe tissue specific promoters
- list polyadenylation signals
- describe SV40 polyadenylation signal
- describe bGH polyadenylation signal
- list enhancer sequences
- describe triple enhancer sequence
- describe ApoAI gene fragment
- list signal peptides
- describe cystatin S signal peptide
- describe Ig secretion signal
- describe vector components
- describe bacterial origin of replication
- describe antibiotic resistance expression cassette
- describe Kanr gene
- describe bla promoter
- describe pUC origin of replication
- describe expression cassette
- describe HBV antigen polynucleotide
- describe upstream sequence
- describe downstream sequence
- describe antibiotic resistance cassette
- describe origin of replication
- describe viral vector
- describe adenoviral vector
- describe Ad26 or Ad35 vector
- describe HBV Pol antigen
- describe truncated HBV core antigen
- describe fusion protein
- describe S-surface antigen
- describe HBV surface antigen
- describe polynucleotide construction
- describe expression vector construction

### Cells, Polypeptides and Antibodies

- provide cells comprising polynucleotides and vectors
- describe method of making HBV antigen
- express and isolate HBV antigen
- provide recombinant polypeptides with HBV antigen sequences
- specify identity levels for SEQ ID NO: 2
- specify identity levels for SEQ ID NO: 4
- specify identity levels for SEQ ID NO: 14
- specify identity levels for SEQ ID NO: 29
- specify identity levels for SEQ ID NO: 27
- provide antibodies specific to non-naturally occurring polypeptides
- define antibody specificity and affinity

### Compositions, Immunogenic Combinations, and Vaccines

- relate to compositions
- describe immunogenic combinations
- define kits
- specify HBV antigens
- provide polynucleotides encoding HBV antigens
- describe vectors encoding HBV antigens
- specify truncated HBV core antigen
- specify HBV Pol antigen
- specify HBV surface antigen
- specify S-surface antigen
- describe composition with truncated HBV core antigen
- describe composition with HBV Pol antigen
- describe composition with HBV surface antigen
- describe composition with S-surface antigen
- describe composition with multiple HBV antigens
- specify vector with truncated HBV core antigen
- specify vector with HBV Pol antigen
- specify vector with HBV surface antigen
- specify vector with S-surface antigen
- describe composition with fusion protein
- specify isolated truncated HBV core antigen
- specify isolated HBV Pol antigen
- specify isolated HBV surface antigen
- specify isolated S-surface antigen
- describe composition with multiple isolated HBV antigens
- specify immunogenic combination with polynucleotides
- describe kit with polynucleotides and vectors
- specify immunogenic combination with HBV surface antigens
- specify immunogenic combination with S-surface antigen
- describe immunogenic combination with multiple HBV antigens
- specify kit with HBV surface antigens
- specify kit with S-surface antigen
- describe kit with multiple HBV antigens
- conclude immunogenic combinations and kits
- define compositions, immunogenic combinations, and vaccines
- describe polynucleotides in immunogenic or vaccine combinations or kits
- describe linked or separate polynucleotides
- describe expression of HBV antigens
- describe fusion antigen production
- describe bicistronic expression vector
- describe separate vectors for polynucleotides
- describe preferred embodiments of vectors
- describe single vector embodiments
- describe immunogenic or vaccine combinations or kits with third and fourth polynucleotides
- describe preferred embodiments of third and fourth vectors
- describe ratios of vectors
- describe additional polynucleotides or vectors
- define anti-HBV agents
- describe effects of anti-HBV agents
- describe pharmaceutically acceptable carriers
- describe excipients
- describe vehicles
- describe routes of administration
- describe formulation for administration
- describe parenteral injections
- describe transmucosal administration
- describe ocular administration
- describe rectal administration
- describe long-acting implantation
- describe sublingual administration
- describe inhalation administration
- describe intranasal administration
- describe preferred embodiments of administration
- describe buffered solutions
- describe pH adjusting and buffering agents
- describe plasmid DNA concentrations
- describe adjuvants
- describe DNA vaccines
- describe RNA vaccines
- describe RNA modification
- describe self-replicating RNA vaccines
- describe adjuvants for co-administration
- describe immune checkpoint inhibitors
- describe toll-like receptor agonists
- describe RIG-1 agonists
- describe IL-15 superagonists
- describe mutant IRF3 and IRF7 genetic adjuvants
- describe STING agonists
- describe FLT3L genetic adjuvant
- describe IL-12 genetic adjuvant
- describe IL-7-hyFc

### Methods of Inducing an Immune Response

- define infection
- define HBV infection
- describe inducing an immune response
- describe therapeutic immunity
- describe protective immunity
- describe immunogenically effective amount
- provide examples of immunogenically effective amount
- describe administration of compositions and immunogenic combinations
- describe prime-boost regimen
- describe ratio of DNA plasmids
- describe preferred subject to be treated
- describe chronic HBV infection
- describe phases of chronic HBV infection
- describe NUC-suppressed subject
- describe preferred subject without advanced hepatic fibrosis or cirrhosis
- describe METAVIR score
- describe fibroscan result
- describe elimination or reduction of chronic HBV
- describe HBV-induced diseases
- describe immunogenically effective amount for HBV-induced diseases
- describe administering another immunogenic agent or anti-HBV agent
- describe examples of anti-HBV agents
- describe CAR-T cells
- describe capsid assembly modulators
- describe cccDNA inhibitors
- describe HBV polymerase inhibitors
- describe other anti-HBV agents
- describe immunomodulators
- describe toll-like receptor modulators
- describe interferon alpha receptor ligands
- describe other HBV treatments

### Methods of Delivery

- describe administration methods
- describe parenteral administration
- describe oral administration
- describe transdermal administration
- describe nasal administration
- describe electroporation
- describe in vivo electroporation devices
- describe electroporation with intramuscular injection
- describe transdermal administration with epidermal skin abrasion
- describe other methods of intracellular delivery

### Adjuvants

- define adjuvants
- introduce adjuvants in immunogenic combinations
- list examples of adjuvants
- describe adjuvants as small molecules or antibodies
- mention adjuvants in separate compositions
- list anti-HBV agents for combination therapy
- describe administration of adjuvants and anti-HBV agents
- mention simultaneous or sequential administration
- summarize adjuvants in compositions and immunogenic combinations

### Methods of Prime/Boost Immunization

- introduce prime-boost regimen
- describe priming and boosting vaccines
- outline administration of priming and boosting vaccines
- mention adjuvants in boosting immunization
- provide example of prime-boost regimen

### Kits

- define kit composition
- describe kit components
- specify polynucleotide sequences
- detail adjuvants and immune stimulants
- outline evaluation methods
- describe in vitro and in vivo assays
- measure cellular immunity
- determine activation status
- assay for antigen-specific T lymphocytes
- describe antibody binding and competition
- measure titers by ELISA
- outline neutralizing antibody assay
- describe ADCP assay
- introduce embodiments section
- define embodiment 1
- specify embodiment 2
- detail embodiment 3
- describe embodiment 4
- outline embodiment 5
- specify embodiment 6
- detail embodiment 7
- describe embodiment 8
- outline embodiment 9
- specify embodiment 10
- detail embodiment 11
- describe embodiment 12
- outline embodiment 13
- specify embodiment 14
- detail embodiment 15
- describe embodiment 16
- outline embodiment 17
- specify embodiment 18
- detail embodiment 19
- describe embodiment 20
- outline embodiment 21
- specify embodiment 22
- detail embodiment 23
- describe embodiment 24
- define kits
- specify embodiment 64
- specify embodiment 65
- specify embodiment 66
- specify embodiment 67
- specify embodiment 68
- specify embodiment 69
- specify embodiment 70
- specify embodiment 71
- specify embodiment 72
- specify embodiment 73
- specify embodiment 74
- specify embodiment 75
- specify embodiment 76
- specify embodiment 77
- specify embodiment 78
- specify embodiment 79
- specify embodiment 80
- introduce embodiments section 2
- specify embodiment 1
- specify embodiment 2
- specify embodiment 3 to 15
- define kits
- specify embodiment 16
- specify embodiment 17
- specify embodiment 18
- specify embodiment 19
- specify embodiment 20
- specify embodiment 21
- specify embodiment 22
- specify embodiment 23
- specify embodiment 24
- specify embodiment 25
- specify embodiment 26
- specify embodiment 27
- specify embodiment 28
- specify embodiment 29
- specify embodiment 30
- specify embodiment 31
- specify embodiment 32
- specify embodiment 33
- specify embodiment 34
- specify embodiment 35
- specify embodiment 36
- specify embodiment 37
- specify embodiment 38
- specify embodiment 39
- specify embodiment 40
- specify embodiment 41
- specify embodiments 42-50

## EXAMPLES

- introduce examples of the application

### Example 1: Generation of HBV Core and Pol Antigen Sequences and Plasmid Optimization

- select HBV core and polymerase proteins as antigens
- generate HBV pol and core antigen consensus sequences
- optimize HBV core antigen by deletion
- optimize HBV pol antigen by changing residues
- codon optimize HBV pol antigen sequence
- test three expression strategies for core and pol antigens
- evaluate post-transcriptional regulatory elements
- select signal peptide for efficient protein secretion
- optimize DNA vaccine vector
- test expression cassettes in pDK plasmid backbone
- evaluate core and pol antigen expression by Western blot
- test plasmids with different expression strategies
- analyze core and pol antigen expression by Western blot
- select optimal plasmids for further testing
- illustrate plasmid constructs

### Example 2: Generation of Adenoviral Vectors Expressing a Fusion of Truncated HBV Core Antigen with HBV Pol Antigen

- design expression cassettes for adenoviral vectors
- include secretion signal and optimize coding sequence
- eliminate homology with human dopamine receptor protein

### Example 3: In Vivo Immunogenicity Study of DNA Vaccine in Mice

- test DNA vaccine in mice
- deliver DNA plasmids via electroporation
- test T-cell responses induced by vaccine
- analyze antigen-specific responses by ELISPOT
- quantify T-cell responses
- test plasmids encoding HBV core and pol antigens
- evaluate T-cell responses against HBV core and pol
- confirm results in a second study
- illustrate T-cell responses

### Example 4: Dose-Finding Study of Combined pDK-Core/pDK-Pol Plasmids in Mice

- evaluate immune responses to combined plasmids
- test different DNA doses
- analyze antigen-specific responses by ELISPOT
- illustrate T-cell responses

### Example 5: Immune Interference Study in Mice

- assess immune interference with combined plasmids
- test plasmids individually and in combination
- analyze antigen-specific responses by ELISPOT

### Example 6: Evaluation of the Efficacy of a DNA Vaccine in Non-Human Primates

- introduce study purpose
- describe vaccine composition
- describe electroporation administration
- describe non-human primate subjects
- describe plasmid administration
- describe electroporation procedure
- describe ELISPOT analysis
- describe intracellular cytokine staining
- present ELISPOT results
- present ICS results
- discuss results
- describe variation in NHP responses
- compare ELISPOT and ICS results
- conclude efficacy of DNA vaccine

### CONCLUSION

- summarize results

### Example 7: Evaluation of the Efficacy of a DNA Vaccine in Human Subjects

- introduce study purpose
- describe human subjects
- describe vaccine composition
- describe electroporation administration
- describe blood sample collection
- describe evaluation of HBsAg levels

### Example 8: In Vivo Immunogenicity Study of Adenoviral Vectors in Mice

- introduce study purpose
- describe adenoviral vectors
- describe in vivo immunogenicity study
- describe administration to F1 mice
- describe splenocyte collection
- describe ELISPOT analysis
- describe peptide pools
- present ELISPOT results
- discuss results
- describe Core and Pol specific T-cell responses
- describe combination of Core Pol fusion and Core adenovectors
- compare adenoviral vectors
- conclude efficacy of adenoviral vectors
- summarize results

